1-3 of 3
Chien-Feng Chen, PhD
Close
Sort by
Journal Articles

Safety Profile of AMG 531 in Healthy Volunteers and in Thrombocytopenic Patients with Immune Thromobocytopenic Purpura.

Daniel E. Stepan, MD, Elaine Sergis-Deavenport, RN, MS, CPNP, Reggie Kelly, BS, Jenny Christal, PhD, Chien-Feng Chen, PhD, Janet L. Nichol, MS
Journal: Blood
Blood (2005) 106 (11): 1240.
https://doi.org/10.1182/blood.V106.11.1240.1240
Published: 2005
Journal Articles

An Open-Label, Unit Dose-Finding Study Evaluating the Safety and Platelet Response of a Novel Thrombopoietic Protein (AMG531) in Thrombocytopenic Adult Patients (Pts) with Immune Thrombocytopenic Purpura (ITP).

Adrian Newland, MD, Marie T. Caulier, MD, Martin R. Schipperus, MD, Maria Kappers-Klunne, MD, Bruno R. Varet, Karen Watkins, BA, Chien-Feng Chen, PhD, Janet L. Nichol, MS
Journal: Blood
Blood (2004) 104 (11): 2058.
https://doi.org/10.1182/blood.V104.11.2058.2058
Published: 2004
Journal Articles

A Phase 2 Placebo Controlled Study Evaluating the Platelet Response and Safety of Weekly Dosing with a Novel Thrombopoietic Protein (AMG531) in Thrombocytopenic Adult Patients (pts) with Immune Thrombocytopenic Purpura (ITP).

David Kuter, MD, DPhil, James B. Bussel, MD, Louis M. Aledort, MD, James George, MD, Roger M. Lyons, MD, George T. Conklin, MD, Alan E. Lichtin, MD, Jorge Nieva, MD, Reggie Kelly, BA, Chien-Feng Chen, PhD, Janet L. Nichol, MS
Journal: Blood
Blood (2004) 104 (11): 511.
https://doi.org/10.1182/blood.V104.11.511.511
Published: 2004